Member Info for market22

Can anyone explain the drop today, I cannot find any news that would have explained why.

Nice to see your comments on our beaded technology board, I am sure we are both looking forward to next year.

In the RNS on the 12th June they say they have increased the sales force to 60 covering 80% of the USA,, my information suggests it has been increased by a further 20 to 80 since the RNS.

It appears the uptrend has been eroded by some selling pressure, this is a regular occurrence when we try to break out. With no news since the launch and no figures due until the 8th October we are a little in the dark with regards to sales. (I am unable to find any news). It is tempting to take some profit but as an acquisition target I am reluctant to do so as the lower the price the more attractive to suitors we become. With Invesco having 29% of the voting rights and Ballie Gifford over 5% this hopefully is reassuring going forward alongside the increase in sales staff from 25 to 80 lets hope we get some news soon.

I am a retired finance director of my own company started from scratch in 1979. I have been following Tissue from the start this company has good management great research teams ( surprised they have held onto such top quality for so long) the potential that is being showed by the development team is above the level it should be the speedy patient applications. The future markets for the products is quiet frankly astounding. I am sure vultures won't let this stock get onto the radar before we have have a takeover bid. 8 years on the board only my second post.